Uncertain — binary market questions and the trades they imply

Pick a side and invest

Resolves Oct 28, 2026 · October FOMC decision

Today's (Oct 27) check, one day before the decision, found the picture still frozen in blackout: markets broadly expect a hold, with CME FedWatch-style readings clustering in the high-70s to low-80s percent for no change (roughly 15-18% for a hike), essentially unchanged from the Oct 16-20 picture built around Warsh's 'I don't prejudge meetings' remark in Bangkok. No policymaker can speak publicly before tomorrow's 2pm ET decision. The hawkish case still rests on Barr's pre-blackout base case for a further hike, Cleveland Fed's Hammack signaling openness to another increase, and 16 of 18 September dots penciling in more tightening this year, while the dovish case leans on September's weak 29K payrolls print, MUFG's explicit skip call tied to the Nov 3 midterms' proximity, and the post-CPI inflation scare having faded rather than built into decision week.

Researched Oct 27, 2026 · tracked since Sep 17, 2026 · 29 readings

38% Sep 17, 202614% Oct 27, 2026

Where consensus sits

14% yes — The Fed hikes again

Holding near a cycle-low hike probability (~14-18%) the day before the decision — in blackout with no fresh catalyst, the number has barely moved since Warsh's Oct 16 silence removed the last pre-decision chance for a hawkish surprise

The hawkish case got fuel from the Oct 14 CPI print: headline inflation accelerated to 3.7% y/y (above forecast) and core also ran hot at 2.6% y/y, Barr's base case already included a further hike, Cleveland Fed's Hammack has separately signaled openness to another increase, and 16 of 18 dots pencil in more hikes this year. The dovish case: September payrolls missed by roughly 55-60K with a rising unemployment rate and downward revisions, MUFG's house call explicitly expects a skip given proximity to the Nov 3 midterms, and market-implied odds have held near a cycle-low hike probability of roughly 13-17% with the inflation scare having faded rather than built into decision week.

What do you think?

30 sources, leaning both ways

nonoradarealestate.com — Fed October rate-hike odds trackerChecked Oct 26: cites Chair Warsh's Oct 16 refusal to preview the decision ('I don't prejudge meetings') with traders pricing roughly 84-87% for a hold, 13-16% for a hike — essentially unchanged from last week.
mixedMNI — 2026 G10 Central Bank CalendarChecked Oct 23: confirms the Fed's Oct 28 decision date alongside the RBNZ and Bank of Canada the same day, with the ECB on Oct 29 and BOJ on Oct 30 — the primary-calendar confirmation this topic's scheduled date rests on.
noInvesting.com — Fed October rate-hike odds slide below 22% ahead of minutesChecked Oct 20: reports CME FedWatch pricing an 82.8% probability the Fed holds on Oct 28 (implying roughly 17.2% for a hike) as of Oct 19 — a further fade from the ~24.9% reading found a day earlier.
noCryptoBriefing — Market raises odds of a 25 bps Fed rate hike to 24.9% ahead of October meetingChecked Oct 19: cites CME FedWatch putting October-hike odds at roughly 24.9%, the most recent reading found at the time — down from the ~35-37% cross-venue level right after the Oct 14 CPI print, suggesting last week's spike has partially faded.
mixedpolitical.org — Fed officials hope to skip an October rate hike, but this week's inflation report could upend that planChecked Oct 19: frames the pre-CPI baseline as officials hoping to skip October, with the Oct 14 inflation report as the swing factor — consistent with the partial-retracement read in this week's odds.
yesCryptoBriefing — Cleveland Fed's Hammack signals potential rate hike to curb inflationChecked Oct 19: Cleveland Fed President Beth Hammack signals openness to a further hike to contain inflation — a hawkish voice still in play after the CPI print, even as cross-venue odds have eased back from their post-CPI peak.
yesBLS — Consumer Price Index, September 2026Released Oct 14, 8:30am ET: headline CPI +0.6% m/m / 3.7% y/y (above the 3.6% forecast, accelerating from August's 3.4%), core +0.3% m/m / 2.6% y/y — a hotter-than-expected print on both the headline and core measures.
yesFXStreet — US CPI hotter than markets wanted: Dollar breaks higher, Gold collapses, crypto softensOct 14: confirms the 3.7%/2.6% CPI prints against 3.6%/2.5% forecasts, gasoline +7.1% m/m as the main headline driver, and the dollar/gold/crypto reaction consistent with markets pricing in a harder-for-longer Fed.
yesCNBC — 10-year Treasury yield jumps as September core inflation comes in hotter than expectedOct 14: 10-year yield up more than 7bps to 5.289% (highest since Oct 8), 2-year up over 10bps to 4.895%; S&P 500 -0.40% and Nasdaq -0.63% at the open — the rates and equity reaction to today's hot print.
mixedInvestinglive — Week ahead: US inflation and retail sales lead a busy economic calendarRe-checked Oct 13: confirms Wednesday's Sept CPI (headline +0.6% m/m / 3.6% y/y expected, core +0.2% m/m / 2.5% y/y) and Thursday's retail sales, PPI, jobless claims and Philly Fed index — the last real data points before the Oct 28 decision, still one day out.
noMUFG Research — September 2026 Fed rates call updateChecked Oct 13: MUFG's house call explicitly expects the Fed to skip October given its proximity to the midterm election, assigning roughly 55-60% odds to a December hike instead — a credible desk's reasoning for why timing, not direction, is the live question.
noPhemex — CME FedWatch: 77.9% Chance Fed Holds Rates in OctoberChecked Oct 3-4: CME FedWatch's hold probability sits at 77.9% (hike ~20%, cut ~2%) — consistent with the post-payrolls level, no further movement.
noCNBC — Traders now see little chance of a Fed rate hike in October after weak jobs reportOct 2: September nonfarm payrolls rose just 29,000 versus forecasts above 80K; CME FedWatch's implied October hike probability fell to roughly 17% from 36% a week earlier, while December hike odds stayed above 75%.
noFXStreet — Nonfarm Payrolls rise by 29K in September vs. 90K expectedOct 2: confirms the 29K payrolls print (vs. 90K expected), unemployment rising to 4.2%, wage growth at 3.0% y/y (vs. 3.2% expected), and a combined 60K downward revision to July-August — a broadly dovish report across every sub-metric.
noCNBC — Fed's preferred gauge showed core inflation at 3.0% in August, much lighter than expectedSept 30: core PCE rose 3.0% y/y (vs. 3.3% expected) and 0.2% m/m (vs. 0.3% expected); headline PCE at 3.4% vs. 3.7% expected — the second dovish data point this week after Williams' remarks, pushing traders to price in less chance of an October hike.
noBabypips — How October Fed Rate Hike Odds Shifted after Mixed U.S. DataChecked Oct 1: CME FedWatch fell to 34.9% for an October hike (from 70.9% a week earlier) after the PCE miss; Kalshi at 34%, Polymarket at 39% hike / 61% hold — all three venues now cluster in the mid-30s.
noSeoul Economic Daily — Fed's No. 2 Says No Rush on Rate Hike, Tilting Odds to Holding in OctoberSept 30: NY Fed President John Williams says there is 'no need for urgency' on another hike and the Fed needs only one more increase 'later this year' (widely read as December), explicitly tilting odds toward an October hold.
noIndexBox — Fed October Rate Hike Odds Fall to 49.4% on Soft Jobs Data, Dovish Williams CommentsSept 30: confirms CME FedWatch's implied October hike probability fell into the mid-40s to roughly 49% from above 70% earlier in the week, attributing the drop to both softer labor data and Williams' remarks.
mixedAvalon Capital Research — Weekly Playbook: Fed Funds Futures Price a 64% Chance of an October Hike Before PCE and PayrollsChecked Sept 28: fed funds futures imply roughly 64% odds of an October hike ahead of this week's PCE and payrolls data — meaningfully below CME FedWatch's ~72% reading the same day.
yesPhemex — Goldman Sachs Forecasts Additional Fed Rate Hike in OctoberSept 17: Goldman Sachs revises its outlook to pencil in 'one additional rate increase in October,' arguing tighter financial conditions persist longer than previously expected — a credible desk moving toward 'yes' the same day this topic opens.
noTheStreet Pro — Why the Fed Isn't Likely to Wait Until OctoberSept 11: argues the Fed hikes in September rather than waiting, explicitly because 'October is even closer to the midterm elections than the upcoming meeting, making it a worse timing option' — the case for skipping October specifically in favor of December.
noYahoo Finance — The market says a Fed rate hike is a done deal. Here's why it might hold steady.Sept 14: Peterson Institute's Adam Posen argues the Fed prefers to wait until December, when 'there'll be no question in anybody's mind — except perhaps the president's — that you have to raise' rates, avoiding the political optics of hiking days before the midterms.
mixedCNBC — Fed meeting recap: Warsh says inflation is still too high as Fed hikes for the first time since 2023Sept 16: confirms the SEP dot plot showing 16 of 18 participants expecting at least one more hike in 2026 (four see two), with Warsh's 30-minute press conference — the shortest since 2011 — giving no explicit guidance on which of the two remaining meetings gets it.
yesKuCoin — Probability of FED October Rate Hike Approaches 50%Sept 17: CME FedWatch's implied October hike probability climbed toward 50%, up from roughly 40% Wednesday morning, as markets digested Warsh's refusal to guide toward skipping the meeting.
yesCME FedWatch ToolChecked Sept 20: implied October hike probability at roughly 59.7%, up from the high-40s two days earlier — the clearest single move of the week toward pricing a second consecutive hike.
yesPhemex — Fed Rate Hike Probability Hits 54.2% for October MeetingChecked Sept 23: CME FedWatch shows a 54.2% probability of a 25bp October hike versus 45.8% for a hold — essentially flat versus the Sept 20-21 readings, confirming the plateau rather than continued climb.
yesInvesting.com (Reuters) — Fed's Barr says future interest rate hikes 'likely' needed to tame inflationSept 23: Barr tells the Chicago Fed housing conference 'in my base case, further policy adjustments are likely to be needed,' citing inflation still above target and not clearly trending toward it — the remark that triggered the day's repricing, with CME FedWatch jumping roughly 14 points the same day.
mixedYahoo Finance (Reuters) — Fed's Williams says it is reasonable to see another US rate hike this yearSept 24: Williams calls another 2026 hike 'reasonable' but stops short of endorsing October specifically, saying the Fed needs more incoming data first — confirms the hawkish shift while withholding a commitment to the exact month.
yesCME FedWatch ToolChecked Sept 24: implied October hike probability at 77.5%, up from roughly 53% on Sept 23 — the sharpest single-day move since this topic opened.
mixedCME FedWatch ToolChecked Sept 25: implied October hike probability at roughly 73.5%, essentially flat versus the prior two days — the post-Barr/CPI repricing has held rather than extended further, with no new Fed speakers or data today.

Open this question on its own page →

Resolves Nov 3, 2026 · 2026 US Senate midterm election day

Today's (Oct 27) check, one week out, still leans on race-by-race ratings rather than market pricing: Cook Political Report's Oct 26 update continues to frame Republicans as holding the overall structural advantage even as it counts seven toss-ups (six Republican-held, one Democratic-held) and has drifted Georgia, North Carolina and Ohio toward Democrats since August. Cook itself projects a net Democratic gain of 2-6 seats this cycle against the 4 needed for control — a range that straddles the control threshold rather than clearly resolving it. Nate Silver's statistical model, last updated in September, remains the most conservative credible estimate on file at 58.6%, up from 50.6% on Sept 6. No fresher individual-race polling was found than the NYT/Siena picture already on record (six Republican-held seats within three points, including a now-even Texas race between Democrat James Talarico and Republican Ken Paxton), and Maine's Democratic nominee is reported inconsistently across outlets (Troy Jackson vs. Graham Platner), a reminder of how thin some of this race-level coverage still is a week out.

Researched Oct 27, 2026 · tracked since Oct 7, 2026 · 15 readings

64% Oct 7, 202660% Oct 27, 2026

Where consensus sits

60% yes — Democrats win the Senate

A genuine toss-up tilting narrowly Democratic — Cook's own seat-gain range (2-6) straddles the 4-seat control threshold, and Silver's cooler 58.6% model pulls the number down from the more bullish race-rating momentum

The case for Democratic control: Cook Political Report has moved Texas, Iowa and Ohio into toss-up territory and Georgia and North Carolina to lean-Democratic since August, Michigan looks solidly blue on every tracker, and a generic midterm swing against the governing party is a well-documented historical pattern. The case for Republican control: Cook itself still frames Republicans as holding the overall advantage and its own projected seat-gain range (2-6) only sometimes clears the 4-seat threshold Democrats need, Nate Silver's model runs noticeably cooler than the race-rating momentum at 58.6%, individual-race aggregators still disagree by double digits on Maine and Texas, and seven toss-ups by definition could break either way on election night.

What do you think?

6 sources, leaning both ways

mixedYahoo News (Cook Political Report) — Cook finds Republicans hold advantage in 2026 Senate races, but Texas and Iowa move to toss-upChecked Oct 26: the nonpartisan Cook Political Report's Aug 20 shift moving Texas and Iowa from lean-Republican to toss-up, bringing its Senate toss-up count to six — while still finding Republicans hold a structural edge overall.
yesMediaite (Cook Political Report) — Cook Political Shifts Four Senate Races Toward Democrats, Key Race Now a Toss-UpChecked Oct 26: reports Cook separately shifting Georgia and North Carolina to 'lean Democratic' and Ohio to toss-up — a run of ratings changes all moving in Democrats' direction.
mixedNewsweek — US midterm election odds tracker: Democrats, Republicans, SenateChecked Oct 26: tracks Nate Silver's statistical model giving Democrats a 58.6% probability of Senate control (last updated in September, up from 50.6% on Sept 6) — the most conservative credible estimate on file relative to the race-rating momentum.
mixedNOTUS — Troy Jackson Will Officially Be Maine's Democratic Senate NomineeChecked Oct 15: confirms Troy Jackson won the Maine Democratic nomination, framing him as a working-class progressive challenger to Collins in one of the cycle's most competitive races.
yesNewsweek — Democrats edge out GOP in polling of 4 critical races to flip SenateChecked Oct 9: cites a NYT/Siena poll showing six Republican-controlled Senate seats within three points, including a now-even Texas race between Democrat James Talarico and Republican Ken Paxton.
noNewsweek — Can Democrats Flip the Senate? Chances 100 Days Out From the MidtermsDocuments Polymarket giving Republicans a 56% chance of retaining the Senate around the 100-day mark — the most recent point at which Republicans were still the favorite, underscoring how much the race has moved since, and a reminder the pricing has reversed before.

Open this question on its own page →

No fixed date · No exchange-confirmed listing date exists; OpenAI confidentially filed a draft S-1 around June 2026 and has been reported eyeing a listing between late 2026 and 2027, but has set no public target date

Today's (Oct 27) check found the same picture, reinforced rather than changed: CFO Sarah Friar's August all-hands framing — public 'in 2027, or sooner' only if the business keeps inflecting — remains the most explicit internal timeline on file, consistent with Altman's Sept 12 Fortune interview explicitly ruling out 2026 and calling a near-term listing 'ill-advised' given AI-safety concerns. Anthropic, OpenAI's closest IPO-race peer, is now reported targeting formal marketing as early as the week of Nov 9 with a debut before Thanksgiving — underscoring that OpenAI itself expects to list second. OpenAI completed its for-profit recapitalization into OpenAI Group PBC in October 2025, with the nonprofit OpenAI Foundation retaining roughly 26% control and the prior cap on investor returns removed — the main structural prerequisite for a conventional IPO remains in place. No public S-1 has yet appeared on EDGAR and no exchange has confirmed a listing date.

Researched Oct 27, 2026 · tracked since Oct 16, 2026 · 8 readings

70% Oct 16, 202654% Oct 27, 2026

Where consensus sits

54% yes — OpenAI completes a US IPO

Nudged down again — nothing has moved the 2027-or-later timeline, and Anthropic's firming Nov 9 marketing start keeps reinforcing OpenAI's position as the slower, more hesitant mover

The case for completing an IPO: the October 2025 restructuring removed the old profit-cap obstacle, OpenAI itself confirmed a confidential S-1 filing, Microsoft and other large investors have a direct financial incentive to see a liquidity event, and the company has never disavowed going public eventually, only the near-term timing. The case against, or for a long delay: Altman has now explicitly ruled out 2026 and cited AI-safety concerns as a reason to hold back, a separate NYT-sourced account says he's also holding out for a $1 trillion valuation floor and rejected listing sooner at a lower price, OpenAI's spokespeople have separately said 'an IPO is not our focus' and that the company could not possibly have set a date, the company's unusual nonprofit-controlled governance could still complicate conventional public-market scrutiny even post-restructuring, and mega-cap tech IPO timelines in this cycle (including this one) have now slipped more than once.

What do you think?

10 sources, leaning both ways

mixedthe-decoder.com — OpenAI planning IPO for late 2026, fears Anthropic might go public firstChecked Oct 26: corroborates CFO Sarah Friar's August all-hands comment that OpenAI would be public 'in 2027, or sooner' if the business keeps inflecting, and that OpenAI's own leadership is watching Anthropic's faster IPO process with concern.
mixedBloomberg Law — Anthropic Weighs IPO in 2027 After Expected Anthropic Public DebutChecked Oct 23: reports Anthropic now aims to begin formal IPO marketing as early as the week of Nov 9, with a debut before Thanksgiving, while OpenAI's own leadership expects Anthropic to list first — a peer-company signal that OpenAI remains the second mover without resolving whether it ever completes its own listing.
noThe Decoder — Altman won't go public for less than $1 trillion, so OpenAI's IPO may slip to 2027Checked Oct 22: covers NYT's sourcing that advisers offered Altman a choice between a $1 trillion valuation (requiring a later listing) or a sooner IPO at a lower price, and that he rejected anything below $1 trillion as a 'nonstarter' — a second, independent account of why the timeline keeps slipping.
noAIWeekly (citing Bloomberg) — OpenAI in talks for $30B at $1.4T, IPO delayed to 2027Checked Oct 21: Bloomberg reports OpenAI is in early talks to raise at least $30B at roughly a $1.4T valuation, with terms fluid and the round explicitly functioning as bridge financing in place of an IPO — no confirmed closing date.
noPulse2 — OpenAI Rules Out 2026 IPO As Sam Altman Prioritizes AI Safety WorkChecked Oct 19: reports Altman's Fortune interview (published around Sept 12, 2026) explicitly ruling out a 2026 listing and citing AI-safety considerations, while not committing to a 2027 date either — the most explicit near-term denial on file so far.
yesForbes Australia — OpenAI says it has filed for IPOChecked Oct 16: OpenAI itself confirms it filed a confidential draft registration statement (Form S-1) with the SEC — the clearest primary-ish confirmation that the IPO process has formally begun.
yesSD Times — OpenAI completes restructuring, strikes new deal with MicrosoftChecked Oct 16: confirms the October 2025 for-profit recapitalization into OpenAI Group PBC, the OpenAI Foundation's ~26% controlling stake, and Microsoft's ~27% stake under the new structure — the deal that removed the main legal obstacle to a conventional IPO.
yesThe Motley Fool — ChatGPT maker OpenAI is headed for a $1 trillion IPOChecked Oct 16: reports on the scale of the targeted IPO valuation and the continued momentum behind the listing process as of July 2026.
noYahoo Finance (Reuters) — OpenAI preparing to file for IPO coming as market awaits SpaceX filingChecked Oct 16: carries OpenAI's own hedge that 'an IPO is not our focus, so we could not possibly have set a date' — the clearest company-sourced skepticism about near-term timing, if not about ever happening.
mixedBNN Bloomberg (Reuters) — OpenAI aiming for speedy IPO, source says, as market awaits SpaceX filingChecked Oct 16: reports the internal timing dispute between Altman (wants to list before Anthropic) and Friar (more cautious), underscoring real uncertainty about pace even amid shared intent to eventually list.

Open this question on its own page →

Resolves Nov 14, 2026 · PDUFA target action date for Summit Therapeutics' BLA covering ivonescimab plus chemotherapy in previously treated, EGFR-mutated non-small-cell lung cancer, based on Phase 3 HARMONi trial data

Today's (Oct 27) check again found no newer reporting than the Fierce Pharma update already on file — Summit's newest OS analysis (data cut June 2026) still stands as the latest data point, putting the Western-subgroup hazard ratio at 0.76 (improved from 0.84 and 0.98 at earlier cuts) but still described as not reaching statistical significance, with the update itself carrying real risk of a major-amendment review extension that could push the actual decision past the Nov 14 date this question resolves against. With 18 days left until Nov 14, no extension has been formally confirmed either way, and the file remains in its routine pre-decision quiet period.

Researched Oct 27, 2026 · tracked since Oct 16, 2026 · 8 readings

45% Oct 16, 202635% Oct 27, 2026

Where consensus sits

35% yes — FDA approves ivonescimab

Tilting against approval by the Nov 14 date — the newest Western-subgroup OS analysis (HR 0.76) is again described as not statistically significant, and the update itself raises real risk of a major-amendment review extension that would push any decision past this question's own deadline

The case for approval by Nov 14: HARMONi met its primary endpoint (progression-free survival) back in 2024, the OS hazard ratio has improved with each successive data cut (0.98 to 0.84 to 0.76), the related HARMONi-2 trial's clearly significant OS win over Keytruda feeds broader confidence in the molecule's underlying mechanism, and Summit has kept engaging the FDA with updated data rather than withdrawing the filing. The case against: the FDA specifically told Summit a statistically significant OS benefit was required and the latest cut still doesn't clear that bar per Fierce Pharma's reporting, the Nov 14 filing rests on HARMONi (not the stronger HARMONi-2 data), the newest analysis plausibly constitutes a major amendment that could trigger a three-month review extension — meaning even a drug the FDA ultimately approves could still resolve 'no' against this specific by-date question — and a comparable prior precedent (Eli Lilly's 2022 CRL for a China-only PD-1 trial) shows the FDA's skepticism toward single-region trial data generally.

What do you think?

6 sources, leaning both ways

noFierce Pharma — Summit Therapeutics updates ivonescimab survival data ahead of FDA decision date (Oct 20 re-check)Re-checked Oct 20: confirms the newest (June 2026 cutoff) Western-subgroup OS hazard ratio improved to 0.76 from 0.84 and 0.98 at earlier analyses, but still 'does not bear statistical significance,' and flags that the update likely constitutes a major amendment that may trigger a three-month review-period extension past the Nov 14 PDUFA date.
yesBusinessWire (Summit Therapeutics) — Summit Therapeutics Announces U.S. FDA Acceptance of Biologics License Application for IvonescimabChecked Oct 16: Summit's own primary-source confirmation of the Jan 29, 2026 BLA acceptance and the Nov 14, 2026 PDUFA target action date this topic resolves against.
noFierce Pharma — Summit Therapeutics updates ivonescimab survival data ahead of FDA decision dateChecked Oct 16: reports the FDA's stated requirement for a statistically significant OS benefit and flags that the updated OS result does not clearly bear statistical significance — the clearest single source carrying this topic's bear case.
yesBusinessWire (Summit Therapeutics) — Updated HARMONi Data Presented at WCLC 2026 Demonstrate Consistent Overall Survival ResultsChecked Oct 16: Summit's Sept 15, 2026 primary-source release citing the OS hazard ratio of 0.78 (nominal p=0.0332) in Western patients, presented as consistent with the Asian-patient cohort.
noThe Motley Fool — Don't buy Summit Therapeutics until this big thing happensChecked Oct 16: skeptical analyst take arguing the regulatory outcome hinges entirely on data Summit had not yet locked down as of the writing, counseling investors to wait for the FDA decision itself.
mixedClinical Trials Arena — Akeso and Summit's ivonescimab meets OS goals in NSCLCChecked Oct 16: covers the separate, more clearly significant HARMONi-2 OS result (HR 0.73, p=0.009) over Keytruda, while distinguishing that this China-only, first-line trial is not the dataset underlying the Nov 14 US filing.

Open this question on its own page →

Resolves Oct 30, 2026 · BOJ Monetary Policy Meeting decision (Oct 29-30, 2026), announced Oct 30

Today's (Oct 27) check, 3 days out, found the same low-probability picture holding: BBH's Oct 19 swaps-based read of under 5% for an Oct 30 hike (and roughly 80% for the Dec 18 meeting) remains the freshest number on file, with no newer swaps print surfacing today. USD/JPY has been range-bound near 152 this week per FXStreet's Oct 22 note, consistent with markets treating Wednesday-Friday's decision as a likely formality. Tokyo core CPI's jump to 2.7% y/y in September (from 1.8%) remains the one hot data point keeping a tail risk of a hawkish surprise alive, but Ueda has given no explicit guidance toward an October move, and a former BOJ official continues to call a January hike more likely than October.

Researched Oct 27, 2026 · tracked since Oct 19, 2026 · 7 readings

26% Oct 19, 202612% Oct 27, 2026

Where consensus sits

12% yes — BOJ hikes in October

Holding near a cycle-low level three days out — the freshest swaps read (BBH, under 5%) is the most dovish on file, with the still-unresolved spread between that and the older ~26% futures-based reading left unreconciled by any new data this week

The case for an October hike: Tokyo core CPI's jump to 2.7% y/y in September adds fresh fuel, Ueda's Sept 18 hike (7-2 vote) shows the Board has the votes to act again quickly, and Ueda himself has warned of yield-curve risk if the Bank is seen moving too slowly. The case for a hold: the most recent swaps readings sit well below last month's levels, a former BOJ official's own house view still points to January as the more likely next move, two Board members already dissented in September, and a December-or-later hike is already heavily priced regardless of what happens this month, reducing the Bank's urgency to act again just six weeks after its last increase.

What do you think?

9 sources, leaning both ways

noFXStreet (BBH) — USD/JPY consolidates near 152Checked Oct 27 (dated Oct 22): USD/JPY range-bound near 152 heading into the Oct 29-30 meeting, consistent with markets treating a hold as the base case and no fresh hawkish catalyst surfacing this week.
mixedVT Markets — Markets eye BoJ October report as yen weakens and futures price one-in-four hike oddsChecked Oct 26 (dated Oct 7): futures priced roughly 26% for an October hike, with most of a full move priced by December — a notably higher read than this week's swaps and prediction-market snapshots, though dated ahead of the September Tokyo CPI print.
noFXStreet (BBH) — Japanese Yen: Range-bound as BoJ stays cautiousChecked Oct 20: BBH's swaps-based read puts October-hike odds at under 5% and December at about 80% — the most recent and most dovish reading found this week, a sharp drop from the ~25-26% this topic carried as of Oct 19.
noVantage Markets — Why USD/JPY stalled: Ueda, Fed hike bets fade (Oct 19, 2026)Checked Oct 20: cites swaps as of Oct 13 pricing roughly 10% for an October hike and about 88% for December — directionally consistent with BBH's even-lower Oct 19-20 reading.
noBabypips — Headline: BOJ rate hike, September 2026 — yen falls, dovish UedaChecked Oct 19: confirms the Sept 18, 2026 25bp hike to 1.25% on a 7-2 vote, and that the yen weakened rather than strengthened because Ueda avoided committing to a near-term follow-up hike — the dovish-guidance backdrop this topic's 'hold' case rests on.
noMNI Markets — MNI INTERVIEW: BOJ Most Likely To Hike In January — MommaChecked Oct 19: a former BOJ official's house view that January is the most likely timing for the next hike, not October — a credible, informed voice landing on 'not yet' for this specific meeting.
mixedFXStreet — The market is pricing a BOJ pause. Here's why Ueda's keep-raising-rates could force a sharp yen repricingChecked Oct 19 (dated Oct 6): futures price roughly a one-in-four chance of an October hike and nearly a full hike by December, with attention shifting to the Oct 29-30 Outlook Report's guidance on pace rather than the decision itself.
noFXStreet — The Japanese yen weakens as traders pare Bank of Japan October hike betsChecked Oct 19 (dated Oct 1): swaps-implied October-hike odds fell below 20% that morning after rising above 30% the prior day, with a full additional hike by December already priced regardless.
yesMNI Markets — MNI POLICY: BOJ's Tankan Raises Hike Odds, Ueda Speech EyedChecked Oct 19: reports the BOJ's Tankan business-sentiment survey running hot enough to lift hike-odds pricing, with Ueda's own public remarks the next catalyst markets are watching for confirmation of near-term intent.

Open this question on its own page →

Resolves Nov 1, 2026 · OPEC+ Nov 1, 2026 meeting, where the group decides December output policy

Today's (Oct 27) check found no new wire reporting beyond what's already on file — the Oct 4 decision to hold November's combined quota unchanged at 31.01 million bpd stands as the latest concrete data point, with UBS analyst Giovanni Staunovo's 'market remains tight' framing still the most recent read on sentiment. The group wants its broader capacity review in hand before resuming increases — a review Iran-war-related disruptions have already delayed once — and Gulf producers are still pumping well below even the unchanged quota amid continuing export disruptions. The Nov 1 meeting, where the group reviews market conditions for December, is now 5 days away. Brent crude remains elevated above $100/barrel, up from roughly $73 before the Iran war began in late February.

Researched Oct 27, 2026 · tracked since Oct 8, 2026 · 13 readings

35% Oct 8, 202621% Oct 27, 2026

Where consensus sits

21% yes — OPEC+ raises the December target

Nudged lower again toward a third straight pause — nothing new surfaced today, and the lack of any fresh bullish signal with the meeting days away reinforces the existing pause lean

The case for a December hike: Brent above $100/barrel gives the group room to add nominal barrels without necessarily crashing prices, Saudi Arabia's documented 2025 strategy of phased increases to regain market share remains the group's broader backdrop once it judges the supply picture safe, and a token December increase could be used to signal confidence ahead of the delayed 2027 capacity review. The case for another pause: the group has already paused twice in a row citing oversupply-glut concerns, a near-identical pause decision last November (for Q1 2026) shows the group is willing to hold steady for an extended stretch rather than resume increases after just one or two months, and Gulf producers are already pumping below even today's unchanged quota because of Iran-war-related export disruptions, leaving little practical reason to raise the nominal target further right now.

What do you think?

7 sources, leaning both ways

noArynews — OPEC+ agrees to keep November oil output targets steadyChecked Oct 26: corroborates the Oct 4 hold decision and cites UBS's Giovanni Staunovo saying the oil market remains tight even with output unchanged, with the Nov 1 meeting set to review December policy.
noUNB — OPEC+ to keep oil output unchanged for second straight month in NovemberChecked Oct 23: corroborates the Oct 4 pause decision and cites a UBS analyst calling it 'in line with market expectations,' with the group's Nov 1 meeting set to decide December policy.
noNairametrics — OPEC keeps November oil production unchanged at 31.01 million bpdChecked Oct 19: confirms the Oct 4, 2026 decision to hold November's combined quota at 31.01 million bpd — the second straight monthly pause this topic's probability now rests on.
mixedEnerdata — OPEC keeps November 2026 production targets unchanged amid supply disruptionsRe-checked Oct 20: ties the pause explicitly to Iran-war-related supply disruptions and confirms the group's next meeting, on Nov 1, will set December policy — the primary near-term checkpoint this topic resolves against. Separately, Reuters-sourced reporting checked today says changes to output are unlikely before 2027 pending the delayed capacity review, reinforcing the pause case.
noQatar Tribune (AP) — Major oil exporters agree to keep production steady in NovemberChecked Oct 19: corroborates the Oct 4 decision and reports Gulf exports fluctuating at 60-80% of normal levels amid the Iran conflict — actual supply already running below the unchanged quota.
noYahoo Finance (Reuters) — OPEC+ pauses oil output hikes beyond December amid glut fearsHistorical precedent, dated Nov 3, 2025: the group's comparable prior decision paused increases for an entire low-demand quarter (Jan-Mar 2026) rather than resuming after just one month — the base-rate pattern behind this topic's lean toward another pause.
yesBusiness Standard — OPEC+ set to agree on another modest increase in crude oil output targetsHistorical context, dated Nov 2025: documents the market-share-regaining strategy behind the group's 2025 phased increases — the broader strategic backdrop that still argues a resumed hike remains on the table once the group judges the glut risk has passed.

Open this question on its own page →

Resolves Dec 12, 2026 · Status of federal appropriations the morning after the Dec 11, 2026 continuing-resolution deadline (H.R. 6500)

Today's (Oct 27) check found Congress still in its pre-midterm posture with no new floor action to report: the Senate Appropriations Committee remains deadlocked along party lines with zero of the twelve FY2027 bills finalized, and House Appropriations Chairman Tom Cole's warning that there isn't enough time left before December stands unchallenged. A bipartisan Senate push — the Lankford-Hassan 'Prevent Government Shutdowns Act,' which would impose an automatic 14-day rolling continuing resolution on any future lapse — remains only a bill, with no sign it could pass and take effect before this December's deadline. The government has already lapsed into a shutdown twice in the prior 13 months (a 43-day shutdown in fall 2025 and another lapse in early 2026), underscoring how real the risk is even with members of both parties publicly campaigning on having 'kept the government open' in September. With Nov 3 midterms now just one week away, Congress has little incentive to negotiate seriously on FY2027 funding before voters go to the polls.

Researched Oct 27, 2026 · tracked since Oct 23, 2026 · 3 readings

34% Oct 23, 202636% Oct 27, 2026

Where consensus sits

36% yes — A shutdown is in effect on Dec 12

Nudged slightly higher — the Senate deadlock remains total with six weeks to the deadline, and the one new legislative fix in play (automatic-CR bill) has no realistic path to enactment before December 11

The case for a shutdown: the Senate Appropriations Committee remains fully deadlocked along party lines with none of the twelve FY2027 bills finalized, Chairman Cole has publicly said there isn't enough time to complete the bills before December, the government has already lapsed into a shutdown twice in the prior 13 months, and the Nov 3 midterms will have just passed, removing the main electoral incentive either party had to avoid a shutdown this time. The case against: the September stopgap passed with overwhelming bipartisan margins (90-6 in the Senate, 370-48 in the House), showing both parties have repeatedly preferred a continuing resolution over a lapse, the House has already passed three of the twelve full-year bills, and members of both parties have publicly taken credit for 'keeping the government open,' suggesting neither side wants to be blamed for a holiday-season shutdown.

What do you think?

4 sources, leaning both ways

mixedThe Daily Signal — Republicans Preemptively Avoid Midterm Government ShutdownChecked Oct 23: confirms the Sept 2026 continuing resolution's strong bipartisan vote margins and its Dec 11 expiration date, while framing it as only a postponement of the underlying funding fight rather than a resolution of it.
yesCitizen Portal — Risk of government shutdown looms as Congress punts key funding decisions to DecemberChecked Oct 23: reports House Appropriations Chairman Tom Cole's warning that the Dec 11 stopgap did not leave enough time to finish FY2027 spending bills, and that the Senate Appropriations Committee remains deadlocked.
noRep. Tim Walberg — Walberg Votes to Keep Government Open and Prevent Another Democrat ShutdownChecked Oct 23: a House Republican's press release claiming credit for the September vote to keep the government open — evidence members on at least one side are actively campaigning on having avoided a shutdown, a incentive that could extend to December.
yesCornyn.senate.gov — Cornyn Cosponsors the Prevent Government Shutdowns ActChecked Oct 26: a sitting senator cosponsoring legislation meant to prevent future shutdowns is itself evidence of how routine and expected the shutdown risk has become this Congress, with two lapses already in the prior 13 months.

Open this question on its own page →

Resolves Oct 28, 2026 · Microsoft fiscal Q1 2027 earnings release, after market close

Tomorrow (Oct 28) after market close is the decision point, one day away. Microsoft confirmed on Oct 7 that it will report fiscal Q1 2027 results then. Back in July, management guided to roughly $50 billion in capex (including finance leases) for the quarter — below the $56.02 billion Visible Alpha consensus at the time — after changing how it accounts for data-center leases (spreading them over 25 years instead of 15), which mechanically lowers reported capex. Sell-side estimates for full fiscal-2027 capex have since run well above the company's own framing: Wolfe Research raised its FY27 capex forecast to $270 billion from $230 billion citing rising AI-memory costs, Truist models $252 billion, and the broader Street consensus sits near $233 billion. Reinforcing the beat case, Microsoft's prior quarter (fiscal Q4 2026, reported in July) saw Azure growth of 43% topping the 39.98% Visible Alpha consensus, a reminder that the company has recently beaten Street modeling on both growth and spend even under cautious guidance.

Researched Oct 27, 2026 · tracked since Oct 26, 2026 · 2 readings

55% Oct 26, 202657% Oct 27, 2026

Where consensus sits

57% yes — Capex beats the Street estimate

Leaning slightly toward a beat heading into tomorrow's print — the pattern of Microsoft outrunning its own cautious guidance (as Azure did last quarter) and the Street's upward capex revisions tilt this a bit past a coin flip

The case for a beat: AI-chip and data-center demand has repeatedly outstripped supply this cycle, Wolfe Research and Truist have both revised their fiscal-2027 capex models higher (to $270B and $252B respectively) citing rising memory costs, and Microsoft has a history of under-promising on quarterly capex only to spend more as GPU allocations and power deals materialize faster than planned. The case for a miss (at or below the $50B guide): management explicitly guided to that lower figure in July after the lease-accounting change, the new 25-year lease amortization mechanically reduces reported capex versus the old methodology, and Microsoft's own CFO commentary has stressed capital discipline amid investor pushback on the pace of AI spending across the sector.

What do you think?

6 sources, leaning both ways

mixedtastylive — Microsoft earnings preview: can Azure justify a $220 billion capex bill?Checked Oct 27: frames tomorrow's print as a direct referendum on whether Azure's growth trajectory justifies the capex run-rate, with heavy investor scrutiny on both the growth and spending lines — consistent with this being read as a genuine coin-flip-adjacent event.
noThe Star (Malaysia) — Microsoft sees strong cash flow, lower capexChecked Oct 26: reports Microsoft's July guidance of roughly $50 billion in fiscal Q1 2027 capex, below the $56.02 billion Visible Alpha consensus at the time, following the shift to 25-year data-center lease amortization from 15 years.
yesTradingpedia — Wolfe cuts Microsoft target on rising AI memory costsChecked Oct 26: Wolfe Research raised its fiscal-2027 Microsoft capex forecast to $270 billion from $230 billion, citing rising AI-memory costs as a reason spending will likely run higher than management's own framing suggests.
mixedMarketBeat — Microsoft earnings are coming, but Azure and capex will decide the reactionChecked Oct 26: reports Truist modeling $252 billion in fiscal-2027 capex versus a Street consensus of roughly $233 billion — sell-side estimates themselves disagree meaningfully on the full-year number.
mixedFinviz — Microsoft announces quarterly earnings release dateChecked Oct 26: carries Microsoft's own Oct 7 press release confirming the Oct 28, 2026 after-market earnings date this question resolves against.
yesBarchart — Microsoft earnings preview: get ready for soaring AI spending to sink MSFT stockChecked Oct 26: argues continued AI-infrastructure demand keeps pushing capex higher than guidance across the sector, framing elevated spending as the more likely outcome even if it pressures the stock.

Open this question on its own page →

No fixed date · FTC filed its notice of appeal Jan 20, 2026 (D.C. Cir. No. 26-5028); briefing is well advanced with the FTC's reply brief filed Sept 29, 2026, but no oral-argument date has been set

Today's (Oct 27) check confirmed the same briefing timeline already on file via the D.C. Circuit's own clerk's-office schedule: the FTC's opening brief (May 22, 2026), Meta's appellee brief (Aug 20, 2026) and the FTC's reply (Sept 29, 2026) are all in, with the deferred appendix due Oct 6, 2026 — briefing is now complete, but no oral-argument date has yet been set. Judge James Boasberg ruled for Meta in November 2025 after a bench trial, finding the FTC had not proven Meta currently holds monopoly power in personal social networking, citing competition from TikTok and other newer platforms, and denying the FTC's request to force a divestiture of Instagram and WhatsApp. A coalition of more than two dozen states led by Texas filed an amicus brief supporting the FTC on May 29, 2026, alongside the Washington Legal Foundation's Aug 27 brief supporting Meta.

Researched Oct 27, 2026 · tracked since Oct 26, 2026 · 2 readings

25% Oct 26, 202625% Oct 27, 2026

Where consensus sits

25% yes — DC Circuit revives the FTC's case

Leaning toward affirmance — Boasberg's findings came out of a full bench trial, and appellate courts generally defer to a trial court's factual findings absent clear error, making a full reversal a genuine uphill climb for the FTC

The case for reviving the claims (yes): the FTC's own reply brief argues the district court applied the wrong legal standard by requiring proof of ongoing monopoly power rather than monopoly power at the time of the challenged conduct, a purely legal question the D.C. Circuit reviews without the usual deference given to factual findings, and the Trump administration's FTC has continued pressing the appeal rather than settling or dropping it. The case for affirmance (no): Boasberg's ruling followed a full bench trial with detailed factual findings on market definition and competitive dynamics, the Washington Legal Foundation and other amici argue the district court's legal analysis was sound, and federal appellate courts have historically been reluctant to overturn well-reasoned bench-trial antitrust rulings on the merits.

What do you think?

6 sources, leaning both ways

noWFAE (NBC News) — Judge sides with Meta in antitrust trial, will not spin off WhatsApp and InstagramChecked Oct 26: confirms Judge Boasberg's November 2025 ruling for Meta, finding the FTC failed to prove current monopoly power and denying the divestiture request — the ruling under appeal.
mixedShacknews (citing reporting) — FTC appeals Facebook (META) antitrust rulingChecked Oct 26: confirms the FTC's Jan 20, 2026 notice of appeal to the D.C. Circuit, beginning the process that could eventually reach the Supreme Court.
noWashington Legal Foundation — Case page: FTC v. MetaChecked Oct 26: WLF's Aug 27, 2026 amicus brief supporting Meta, asking the D.C. Circuit to uphold the district court's rejection of the FTC's monopolization claim.
yesCourtListener — D.C. Circuit docket No. 26-5028, briefing orderChecked Oct 27: the clerk's April 2026 scheduling order and docket confirm a May 29, 2026 amicus brief from a 25-plus-state coalition led by Texas supporting the FTC, alongside the briefing deadlines already on file — a reminder the pro-revival side has real institutional backing too.
yesMLex — US FTC files reply in support of restarting monopoly case against MetaChecked Oct 26: reports the FTC's Sept 29, 2026 reply brief arguing Section 13(b) of the FTC Act doesn't require proof of an ongoing violation at the time of a final decision — the core legal argument for reversal.
mixedWebProNews — FTC appeals dismissal of antitrust lawsuit against Meta over acquisitionsChecked Oct 26: background on the FTC's decision to appeal rather than drop the case, framing the odds of success as genuinely contested given the deference bench-trial findings usually receive.

Open this question on its own page →

No fixed date · Commerce's required update on domestic copper markets was due by June 30, 2026 and reportedly recommended a phased tariff (15% rising to 30%); as of September 2026 reporting the White House had made no final decision, and no proclamation has been issued as of this run

The original July 2025 Section 232 proclamation imposed a 50% tariff on semi-finished copper products but carved out refined copper (including cathodes) pending a separate Commerce review. That review recommended a phased universal duty — 15% starting January 1, 2027, rising to 30% in 2028 — but Reuters reported on Sept 10, 2026 that the White House's plan had 'stalled amid affordability concerns,' with an administration official saying no final decision had been made. Freeport-McMoRan's CEO said as recently as this cycle that the company is still waiting for tariff details; Freeport itself didn't push a specific recommendation in its Commerce survey response, while Trafigura urged keeping refined copper tariff-free until new US capacity comes online and the Copper Development Association sought exemptions. When the hesitation story broke, Freeport shares fell about 7% and copper prices eased, underscoring how much is actually priced on this decision.

Researched Oct 27, 2026 · tracked since Oct 27, 2026

Where consensus sits

20% yes — Trump imposes the refined-copper tariff

Leaning no — a market-based read (the COMEX-LME price spread) implies only a mid-teens probability for the January 2027 duty, consistent with Reuters' reporting that the plan has stalled inside the White House over affordability concerns

The case for a tariff: Commerce's own mandated review recommended the phased duty, the administration has shown a consistent preference for using Section 232 to reshore metals production, and domestic smelters/recyclers have an obvious profit incentive to lobby for it. The case against: Reuters reports the White House itself has stalled the plan over consumer-affordability concerns, Société Générale's analysis of the COMEX-LME copper price spread implies only a 14.6% market-priced probability of the 15% tariff taking effect in January 2027, and major industry voices (Freeport, Trafigura, the Copper Development Association) have either declined to lobby for it or actively argued against immediate implementation.

What do you think?

5 sources, leaning both ways

noKFGO/WSAU (Reuters) — White House copper tariff plan stalls amid affordability concerns, sources sayChecked Oct 27: reports the White House has not made a final decision and that imposing the refined-copper tariff is 'not a foregone conclusion'; Freeport shares fell about 7% and copper prices eased on the news.
noING (think.ing.com) — What's next for US copper import tariffsChecked Oct 27: cites Société Générale's estimate that the COMEX-LME copper price spread implies roughly a 14.6% probability of the 15% tariff taking effect in January 2027 and 37% for the 30% duty in January 2028 — a market-based (not prediction-market) probability read.
mixedWhite & Case — President Trump Orders 50 Percent Section 232 Tariff on Copper ImportsChecked Oct 27: law-firm summary of the July 2025 proclamation, confirming refined copper's carve-out pending the Commerce Secretary's market update and the phased 15%/30% structure under consideration.
yesFox News (opinion) — Trump is taking decisive action to bring this critical industry back to American soilChecked Oct 27: administration-aligned framing arguing the copper tariff program is a deliberate reshoring strategy, representing the pro-tariff case even though it predates the September stall report.
mixedCreamer Media/Benzinga — Freeport-McMoRan still waiting for US copper tariff details, CEO saysChecked Oct 27: Freeport's own CEO says the company is still waiting for tariff details rather than assuming either outcome — direct evidence from the industry's largest potential beneficiary that this remains genuinely undecided.

Open this question on its own page →

No fixed date · The three agencies re-proposed the rule on March 19, 2026; the public comment period closed June 18, 2026; Bloomberg Intelligence has projected possible finalization in late 2026 with phase-in from 2027, but no agency has set a public target date

Federal banking regulators re-proposed Basel III Endgame on March 19, 2026, describing it as the most significant reset to the capital regime in more than a decade, with lower minimum risk weights, less conservative methodologies and a narrower market-risk framework expected to reduce overall capital requirements industry-wide — a sharp contrast to the original 2023 version, which raised requirements and drew heavy bank opposition before stalling for years. The public comment period closed June 18, 2026, and Fed Governor Michelle Bowman has said changes to capital rules are 'coming soon,' but no agency has committed to a specific finalization date. No final rule had been issued as of this run.

Researched Oct 27, 2026 · tracked since Oct 27, 2026

Where consensus sits

60% yes — Regulators finalize the rule

Leaning toward eventual finalization — this version lowers rather than raises capital requirements, giving regulators and banks aligned incentives to finish it, but the original proposal's multi-year stall is a real precedent for delay

The case for finalization: this re-proposal is explicitly bank-favorable (lower capital requirements rather than higher), removing the intense industry opposition that stalled the 2023 version for years, Governor Bowman has publicly signaled the agencies intend to move soon, and the comment period has already closed. The case against, or for further delay: the original 2023 Basel III Endgame proposal took more than two years and was ultimately scrapped rather than finalized in its original form, the UK has already pushed back its own Basel timeline specifically citing US delay as the reason, and no agency has committed to any public target date even four months after the comment period closed.

What do you think?

5 sources, leaning both ways

mixedLearnSignal — Basel III Endgame Explained: What Changed in the 2026 US Capital RulesChecked Oct 27: explainer on the March 2026 re-proposal's key changes from the original 2023 draft, describing it as a simplification and recalibration rather than a capital increase.
mixedSuade — US regulators unveil Basel Endgame detailsChecked Oct 27: confirms the three March 19, 2026 proposals (large international banks, other banks, and mortgage activity), the June 18 comment-period close, and that no final effective date has been set.
mixedDeloitte — Basel final rules: takeaways and highlights for US banksChecked Oct 27: industry-advisory analysis of the re-proposal's likely effects on bank capital planning, written on the assumption finalization is coming but without a confirmed date.
yesIndependent Banker — Fed's Bowman: Changes to capital rules coming soonChecked Oct 27: Fed Governor Michelle Bowman publicly signals the agencies intend to finalize capital-rule changes soon — the clearest regulator-sourced statement of intent on file.
noBanking Exchange — UK Postpones Basel Rules Due to US DelayChecked Oct 27: documents a foreign regulator explicitly adjusting its own Basel implementation timeline because of US delay — direct evidence the US rulemaking process has a real history of slipping its own informal targets.

Open this question on its own page →

Resolves Mar 3, 2027 · PDUFA target action date for Exelixis's NDA covering zanzalintinib plus atezolizumab in previously treated metastatic colorectal cancer, based on Phase 3 STELLAR-303 data; extended three months from the original Dec 3, 2026 date after the FDA requested updated efficacy and safety data

The FDA accepted Exelixis's NDA for standard review on Feb 2, 2026, based on the Phase 3 STELLAR-303 trial, which showed zanzalintinib plus atezolizumab improving overall survival over regorafenib (stratified hazard ratio 0.80; median OS 10.9 vs. 9.4 months) in previously treated, non-MSI-high metastatic colorectal cancer. On Sept 11, 2026, Targeted Oncology reported the FDA extended the PDUFA date by three months, to March 3, 2027, to review updated efficacy and safety data Exelixis submitted — the agency gave no public reason beyond needing more time. The trial missed significance on one of its dual primary endpoints in a subgroup, and severe or life-threatening adverse events occurred in 59% of the zanzalintinib arm versus 37% on regorafenib. William Blair's analysts have characterized overall rejection risk as low given the broadly positive data, while Leerink has flagged a risk the FDA could carve out the non-liver-metastatic subgroup from any approval.

Researched Oct 27, 2026 · tracked since Oct 27, 2026

Where consensus sits

55% yes — FDA approves zanzalintinib for mCRC

A genuine coin-flip-adjacent call — sell-side analysts see low rejection risk on the merits, but the FDA's own three-month extension to request more data is a real cautionary signal that keeps this from being a clear 'yes'

The case for approval: STELLAR-303 showed a statistically significant overall survival benefit in its primary analysis, William Blair's analysts believe rejection risk remains low given the broadly positive data, and Exelixis changed nothing about the underlying trial results when the FDA asked for updated data. The case against: the FDA's extension request itself signals unresolved questions, the trial missed statistical significance on a dual-primary-endpoint subgroup analysis, severe adverse events ran notably higher on zanzalintinib (59%) than on regorafenib (37%), and Leerink has flagged a real risk the agency excludes the non-liver-metastatic subgroup from any approved label.

What do you think?

5 sources, leaning both ways

mixedOncLive — FDA Accepts NDA for Zanzalintinib Plus Atezolizumab in Pretreated mCRCChecked Oct 27: confirms the Feb 2, 2026 FDA acceptance of the NDA under standard review with the original Dec 3, 2026 PDUFA date, based on STELLAR-303.
yesExelixis (ir.exelixis.com) — NDA acceptance press releaseChecked Oct 27: Exelixis's own primary-source confirmation of FDA acceptance and the regulatory timeline this topic tracks.
noTargeted Oncology — FDA Delays Decision on Zanzalintinib Combo for mCRCChecked Oct 27: reports the FDA's Sept 11, 2026 three-month PDUFA extension to March 3, 2027, to review updated efficacy and safety data — the clearest source of this topic's bear case.
mixedFierceBiotech — FDA delays approval decision for Exelixis' tyrosine kinase inhibitor in colorectal cancerChecked Oct 27: covers the PDUFA delay while citing William Blair's view that overall rejection risk remains low given the promising Phase 3 data.
noFierceBiotech — Exelixis' Cabometyx successor fails primary endpoint colorectal cancer trial amid FDA reviewChecked Oct 27: details the dual-primary-endpoint subgroup miss and the elevated severe-adverse-event rate (59% vs. 37% for regorafenib) underlying the bear case.

Open this question on its own page →

Resolved

October 202624 questions

September 20267 questions

August 20263 questions